UnitedHealth, FTC reach proposed settlement in insulin case

Emily Olsen / healthcaredive - The tentative deal comes months after CVS Health reached a proposed settlement in the lawsuit alleging major pharmacy benefit managers are inflating insulin costs.

AI Summary: UnitedHealth/Optum Rx reached a proposed settlement with the FTC over alleged anti-competitive insulin rebate and pricing practices, including terms to resolve claims that rebates harmed competition and patients. The agreement would curb disputed pharmacy benefit manager conduct and could reshape how insulin discounts are negotiated and passed through to consumers.

#healthcare #pharmaceuticals #drugpricing #governmentpolicy #healthcarefinance #pricetransparency #healthdisparities #diabetes

Back to Top / Fri, June 12, 2026, 5:22 pm / permalink 25231 / 5 stories in 28 days /




Related Stories


Thousands of Medicare beneficiaries unexpectedly lose 'free' drug plans / 10 hrs

Bill would let patient drug spending count toward insurance deductibles / 2 months

340B discounts face reform as profits outpace patient benefit / 2 months

AbbVie sues HHS over 340B patient definition and guidance / 3 months

Medicare GLP‑1 expansion spurs retailer programs and policy debate / 13 days

CVS sues Tennessee over PBM‑pharmacy separation law / 6 wks

Optum Rx launches transparent PBM model, delinking drug prices from fees / 1 month

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Health Disparities, Product Recall, Vitamin D, Supply Chain and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.